Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Danny Bluestein
State University New York Stony Brook, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Polynova Cardiovascular
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Bluestein's research will use a Polynova transcatheter aortic valve that is specially designed for the project and it will be studied in order to offer a solution for biscuspid aortic valve patients. The university is the owner of the intellectual property and Polynova has a license to the technology.
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes
Narrative Calcific aortic valve disease (CAVD) is a major health issue that can lead to severe aortic stenosis and heart failure if untreated. Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for inoperable CAVD patients, often as their only life-saving alternative. However, complications such as calcification, valve migration, conduction abnormalities, and paravalvular leaks leading to increased stroke risk have limited TAVR utility and anticipated expansion into younger patients, including those with Bicuspid Aortic Valve (BAV) disease, a congenital disease marked by earlier incidence of CAVD. Our translational project aims to develop the next generation of TAVR technology, by combining imaging, computational, and in vitro tools into an optimization approach that will guide pre-planning and tailor TAVR procedures for achieving significantly better patient outcomes and reduce ensuing complications. We also aim to offer a disruptive technology ? next generation polymeric valves specifically optimized for TAVR.
Filed on September 21, 2018.
Tell us what you know about Danny Bluestein's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.